Immune-related diseases are disorders caused by abnormal immune system functioning, which can be classified into autoimmune diseases (where the immune system attacks the body's own tissues), allergic diseases (where the immune response is excessive), and immunodeficiency diseases (where the immune function is insufficient). Common diseases include rheumatoid arthritis, asthma, AIDS, etc., and they require intervention through medication, immune regulation or replacement therapy.

 As an innovative biopharmaceutical research and development enterprise, the company is dedicated to the research and development of breakthrough therapies for major immune-related diseases. It is currently advancing the world's only clinically validated T-cell function resetting drug, which is expected to bring new treatment options to various difficult-to-treat diseases such as rejection after organ transplantation, autoimmune diseases, and AIDS.

This class of core products utilizes a differentiated T-cell precision depletion technology. Through a unique bivalent fusion protein design, it significantly enhances target binding affinity and potency, selectively eliminating pathogenic T cells without affecting other lymphocytes. This breakthrough overcomes the key limitations of existing T-cell depletion therapies, namely high toxicity and insufficient selectivity.

The company has established deep strategic partnerships and "industry-academia-research" collaborations with numerous premier scientific research institutes and clinical centers both domestically and internationally. These partners include the H. Lee Moffitt Cancer Center (a National Cancer Institute-designated comprehensive cancer center), the National Institutes of Health (NIH), the University of Colorado, Thomas Jefferson University, and hospitals affiliated with Zhejiang University School of Medicine. Together, these collaborations have formed a comprehensive innovation ecosystem spanning basic research, clinical translation, and industrialization.

Currently, the drug is undergoing its pivotal Phase III trial prior to market launch. Concurrently, the company maintains a robust pipeline with multiple clinical programs in Phase I-II. Over the next three years, the company plans to disclose a series of key clinical data readouts and advance towards regulatory submission.According to projections by professional evaluation agencies, the core product holds a global market potential exceeding $5 billion post-approval, demonstrating substantial long-term commercial value and growth trajectory.

We sincerely invite leading industrialization partners and investment institutions to join hands with us in advancing the development of this project.